Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bone graft & orthobiologics cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 12% on average (190 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 42 | 1,926 | 47% |
| 2020 | 39 | 1,554 | 49% |
| 2021 | 33 |
Graft add-on codes identify surgeons using biologics across spine and extremity cases. Professional codes (what the surgeon bills): CPT 20930, 20931, 20936, 20937, 20938, 20939.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 63% of the cases CMS names in Pennsylvania; 16 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 21 | 796−5%/yr | −5%/yr | 0.4 | 1% | 810 in 2030+0.2%/yr |
| Massachusetts | 14 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 643 | 120,771−1.4%/yr | −1.4%/yr | 84.30.9× | 52% | 123,700 in 2030+0.4%/yr |
Bone graft & orthobiologics in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
| 2024 |
| 1,024 |
| 58% |
| 2025 est. | ≈ 990 | – |
| 2026 est. | ≈ 1,010 | – |
| 1,457 |
| 51% |
| 2022 | 30 | 1,240 | 53% |
| 2023 | 32 | 1,179 | 56% |
| 2024 | 25 | 1,024 | 58% |
| 2025 from claims | – | 995 913–1,053 | 59% |
| 2026 forecast | – | 1,009 888–1,164 | 59% |
| 2027 forecast | – | 1,010 863–1,204 | 59% |
| 2028 forecast | – | 1,011 843–1,238 | 60% |
| 2029 forecast | – | 1,012 826–1,269 | 60% |
| 2030 forecast | – | 1,012 811–1,297 | 61% |
In 2025, 76% inpatient hospital, 24% hospital outpatient.
| 581−11%/yr |
| −11%/yr |
| 0.6 |
| 0% |
| 650 in 2030+1.9%/yr |
| Connecticut | 5 | 234−7.1%/yr | −7.1%/yr | 0.7 | 0% | 240 in 2030+0.2%/yr |
| New Jersey | 3 | 173−18%/yr | −18%/yr | 0.2 | 1% | 170 in 2030−0.7%/yr |
| 30 |
| 9,758+2.6%/yr |
| +2.6%/yr |
| 4.20.8× |
| 75% |
| 13,200 in 2030+5.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Kuros Biosciences leads with 30% of company spending on these surgeons in 2025, +13 pts on 2024.
In 2025, 15 companies reported engagement with Pennsylvania’s surgeons worth $298K in consulting, speaking, meals and travel tied to these products, about $12K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.